74440-53-2

Upstream product

• 110-91-8 morpholine 
• 50-00-0 formaldehyd 
• 4008-48-4 nitroxoline 
• 3565-26-2 5-nitroso-8-hydroxyquinoline 
• 148-24-3 8-quinolinol 

Relevant academic research and scientific papers

8-hydroxyquinoline compound as well as preparation method and application thereof in preventing and treating agricultural disease

The invention discloses a hydroxyquinoline compound as well as a preparation method and application thereof in preventing and treating agricultural diseases. Testing results show that the compound hasremarkable activity upon corn leaf fulvia fulvum, cotton oxysporum, potato rhizoctonia solani kuhn, didymella bryoniae, fusarium oxysporum, wheat gibberella, rice blast, botrytis cinerea, lycium barbarum anthracnose, cotton anthracnose, sclerotinia sclerotiorum, pepper phytophthora blight, potato late blight, rhizoctonia solani, melon bacterial fruit plaque bacteria, grape meloidogynosis bacteria, Chinese cabbage erwinia carotovora, kiwi fruit anabrosis bacteria, pseudomonas lachrymans, ralstorinia solanacearum, rice bacterial leaf blight and rice bacterial stripe bacteria. The hydroxyquinoline compound is simple in preparation process, cheap and easy in raw material obtaining, high in product purity, good in bioactivity and wide in sterilization spectrum and has the potential of being developed as new fungicides.

Synthesis and anti-phytopathogenic activity of 8-hydroxyquinoline derivatives

Phytopathogenic fungi have become a serious threat to the quality of agricultural products, food security and human health globally, necessitating the need to discover new antifungal agents with de novo chemical scaffolds and high efficiency. A series of 8-hydroxyquinoline derivatives were designed and synthesized, and their antifungal activity was evaluated against five phytopathogenic fungi. In vitro assays revealed that most of the tested compounds remarkably impacted the five target fungi and their inhibitory activities were better than that of the positive control azoxystrobin. Compound 2, in particular, exhibited the highest potency among all the tested compounds, with an EC50 of 0.0021, 0.0016, 0.0124, 0.0059 and 0.0120 mM respectively against B. cinerea, S. sclerotiorum, F. graminearum, F. oxysporum and M. oryzae, followed by compound 5c. The morphological observations of optical microscopy and scanning electron microscopy revealed that compounds 2 and 5c caused mycelial abnormalities of S. sclerotiorum. Futhermore, the results of in vivo antifungal activity of compounds 2 and 5c against S. sclerotiorum showed that 5c possessed stronger protective and curative activity than that of 2, and the curative effects of 5c at 40 and 80 μg mL-1 (84.18% and 95.44%) were better than those of azoxystrobin (77.32% and 83.59%). Therefore, compounds 2 and 5c are expected to be novel lead structures for the development of new fungicides.

Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents

Methionine aminopeptidase (MetAP) is a class of ubiquitous enzymes essential for the survival of numerous bacterial species. These enzymes are responsible for the cleavage of N-terminal formyl-methionine initiators from nascent proteins to initiate post-translational modifications that are often essential to proper protein function. Thus, inhibition of MetAP activity has been implicated as a novel antibacterial target. We tested this idea in the present study by targeting the MetAP enzyme in the obligate intracellular pathogen Rickettsia prowazekii. We first identified potent RpMetAP inhibitory species by employing an in vitro enzymatic activity assay. The molecular docking program AutoDock was then utilized to compare published crystal structures of inhibited MetAP species to docked poses of RpMetAP. Based on these in silico and in vitro screens, a subset of 17 compounds was tested for inhibition of R. prowazekii growth in a pulmonary vascular endothelial cell (EC) culture infection model system. All compounds were tested over concentration ranges that were determined to be non-toxic to the ECs and 8 of the 17 compounds displayed substantial inhibition of R. prowazekii growth. These data highlight the therapeutic potential for inhibiting RpMetAP as a novel antimicrobial strategy and set the stage for future studies in pre-clinical animal models of infection.

Discovery of inhibitors of Burkholderia pseudomallei methionine aminopeptidase with antibacterial activity

Evaluation of a series of MetAP inhibitors in an in vitro enzyme activity assay led to the first identification of potent molecules that show significant growth inhibition against Burkholderia pseudomallei. Nitroxoline analogues show excellent inhibition potency in the BpMetAP1 enzyme activity assay with the lowest IC50 of 30 nM and inhibit the growth of B. pseudomallei and B. thailandensis at concentrations ≥31 μM.

8-hydroxyquinolines as inhibitors of cathepsin B

This invention relates to the compounds or a pharmaceutical acceptable salts, hydrates or solvates thereof, which are inhibitors of cysteine proteases, in particular of cathepsin B. Compounds of the invention are useful in the treatment of diseases in which cathepsin B is implicated, such as cancer, rheumatoid arthritis, osteoarthritis, osteoporosis, pancreatitis, immune and neurodegenerative diseases, e.g. Alzheimer's disease.

Biologically active Mannich bases derived from nitroxoline.

A series of compounds with various basic side chains were derived from 5-nitro-8-hydroxyquinoline (nitroxoline). Aminomethylation of nitroxoline led exclusively to the formation of o-substituted phenolic Mannich bases. Depending on the kind of the primary